Return to homepagePandemic Pact

Preclinical Toxicology Testing and IND application for a Novel Cholera Conjugate Vaccine

Grant number: 221595/Z/20/Z

Grant search

Key facts

  • Disease

    Cholera

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $595,871.29

  • Funder

    Wellcome Trust

  • Principal Investigator

    Dr. Julia Lynch

  • Research Location

    South Korea

  • Lead Research Institution

    International Vaccine Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

This grant award would ensure timely completion of a required toxicology study and development on an IND application in support of a first in human trial of this novel vaccine. This funding will advance a vaccine with the potential to enable sustained cholera control in high risk settings by inducing durable immunity across all ages including infants and toddlers at low cost, reducing cholera burden among the world's most vulnerable populations.

2 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Vaccination of Rabbits with a Cholera Conjugate Vaccine Comprising O-Specific Polysaccharide and a Recombinant Fragment of Tetanus Toxin Heavy Chain Induces Protective Immune Responses against Vibrio cholerae O1.

Scalable production and immunogenicity of a cholera conjugate vaccine.